Trametinib (DMSO solvate)
Trametinib (DMSO solvate), also known as GSK1120212, is a highly potent and selective allosteric inhibitor of MEK1 and MEK2 kinases with an IC50 of 2 nM. It is widely used in both in vitro and in vivo cancer research, particularly for studying the MAPK/ERK pathway in melanoma, NSCLC, and other malignancies.
Product Specifications
CAS Number
1187431-43-1
Product Name Alternative
Type, Trametinib, Trametinib (DMSO solvate), Trametinib dimethyl sulfoxide, Trametinib DMSO solvate, JTP74057, JTP-74057, JTP-74057 (DMSO solvate), JTP 74057, inhibit, Mitogen-activated protein kinase kinase, orally, Inhibitor, MEK1/2, MEK, MAPKK, MAP2K, GSK 1120212, GSK1120212, GSK-1120212, GSK-1120212 (DMSO solvate), AIA, Adjuvant-induced, arthritis, Apoptosis, CIA, collageninduced, DMSO solvate
Field of Research
Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
98.82% (May vary between batches)
Solubility
DMSO:1.3 mg/mL (1.87 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.44 mM)
Smiles
CS (C) =O.CC (=O) Nc1cccc (c1) -n1c2c (C) c (=O) n (C) c (Nc3ccc (I) cc3F) c2c (=O) n (C2CC2) c1=O
Molecular Formula
C28H29FIN5O5S
Molecular Weight
693.53
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
